How to buy Affimed N-V stock | $6.26

Affimed N.V is a biotechnology business based in the US. Affimed N-V shares (AFMD) are listed on the NASDAQ and all prices are listed in US Dollars. Affimed N-V employs 153 staff and has a trailing 12-month revenue of around 0.00.

Affimed N-V stock price (NASDAQ: AFMD)

Use our graph to track the performance of AFMD stocks over time.

Affimed N-V shares at a glance

• Key figures

Information last updated 2021-09-19.

Latest market close	$6.26
52-week range	$3.09 - $11.74
50-day moving average	$6.50
200-day moving average	$7.85
Wall St. target price	$14.75
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-0.43

Buy Affimed N-V shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Affimed N-V stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Affimed N-V price performance over time

Historical closes compared with the close of $6.26 from 2021-09-24

1 week (2021-09-17)	-2.03%
1 month (2021-08-25)	-5.15%
3 months (2021-06-25)	-24.03%
6 months (2021-03-26)	-19.43%

1 year (2020-09-25)	87.99%
2 years (2019-09-25)	83.58%
3 years (2018-09-25)	36.09%
5 years (2016-09-23)	112.93%

Affimed N-V financials

Revenue TTM	$42.6 million
Gross profit TTM	$28.9 million
Return on assets TTM	-12.51%
Return on equity TTM	-39.9%
Profit margin	-89.61%
Book value	$1.26
Market capitalisation	$765.1 million

TTM: trailing 12 months

Shorting Affimed N-V shares

There are currently 4.2 million Affimed N-V shares held short by investors – that's known as Affimed N-V's "short interest". This figure is 13% up from 3.8 million last month.

There are a few different ways that this level of interest in shorting Affimed N-V shares can be evaluated.

Affimed N-V's "short interest ratio" (SIR)

Affimed N-V's "short interest ratio" (SIR) is the quantity of Affimed N-V shares currently shorted divided by the average quantity of Affimed N-V shares traded daily (recently around 1.1 million). Affimed N-V's SIR currently stands at 3.81. In other words for every 100,000 Affimed N-V shares traded daily on the market, roughly 3810 shares are currently held short.

However Affimed N-V's short interest can also be evaluated against the total number of Affimed N-V shares, or, against the total number of tradable Affimed N-V shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Affimed N-V's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Affimed N-V shares in existence, roughly 40 shares are currently held short) or 0.0364% of the tradable shares (for every 100,000 tradable Affimed N-V shares, roughly 36 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Affimed N-V.

Find out more about how you can short Affimed N-V stock.

Affimed N-V share dividends

We're not expecting Affimed N-V to pay a dividend over the next 12 months.

Affimed N-V share price volatility

Over the last 12 months, Affimed N-V's shares have ranged in value from as little as $3.085 up to $11.74. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Affimed N-V's is 2.6468. This would suggest that Affimed N-V's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Affimed N-V overview

Affimed N. V. , a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead product candidate is AFM13, which has completed Phase II clinical study of CD30-positive T-cell lymphoma, and hodgkin lymphoma (HL), as well as is in Phase II clinical trials for peripheral T-cell lymphoma, and transformed mycosis fungoides; that is in Phase I clinical study in combination with adoptive NK cells for CD30-postive lymphomas; and has completed Phase Ib clinical study in combination with anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed HL. The company is also developing AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase I/IIa clinical trials for the treatment of advanced cancer patients; and AFM26, an innate cell-engaging bispecific antibody targeting B cell maturation antigen (BCMA) for the treatment of multiple myeloma. The company has collaboration agreements with The University of Texas MD Anderson Cancer Center; Genentech, Inc. ; Roivant Sciences Ltd.

Frequently asked questions

What percentage of Affimed N-V is owned by insiders or institutions?
Currently 2.771% of Affimed N-V shares are held by insiders and 67.147% by institutions. How many people work for Affimed N-V?
Latest data suggests 153 work at Affimed N-V. When does the fiscal year end for Affimed N-V?
Affimed N-V's fiscal year ends in December. Where is Affimed N-V based?
Affimed N-V's address is: Technologiepark, Heidelberg, Germany, 69120 What is Affimed N-V's ISIN number?
Affimed N-V's international securities identification number is: NL0010872420 What is Affimed N-V's CUSIP number?
Affimed N-V's Committee on Uniform Securities Identification Procedures number is: N01045108